Published in Health Business Week, December 28th, 2007
Alan Kessman, Chief Executive Officer, said, "We are extremely pleased with these preliminary data. Based on these data at this time, we believe that we have achieved the targeted response rate for this study." He added, "It remains our plan to file a new drug application with the U.S. Food and Drug Administration in 2008 based on the data from this...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.